Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews · Urology

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 50%Moderate 1 · 50%High 0 · 0%

Immune checkpoint inhibitors vs any first‐line chemotherapy

Time to death from any cause Range of · participants with advanced or metastatic muscle invasive bladder cancer

Immune checkpoint inhibitors showed no clear difference in time to death from any cause Range of compared with any first‐line chemotherapy (moderate certainty).

1 finding from 1 review

Immunotherapy for advanced or metastatic urothelial carcinoma 2023 · Cochrane Headline outcomes only
HR 0.97 [0.87, 1.07]
3 studies · 2068 participants
Moderate

Immune checkpoint inhibitors vs any second‐line chemotherapy

Time to death from any cause Range of · participants with advanced or metastatic muscle invasive bladder cancer

Immune checkpoint inhibitors may leads to lower time to death from any cause Range of compared with any second‐line chemotherapy (low certainty).

1 finding from 1 review

Immunotherapy for advanced or metastatic urothelial carcinoma 2023 · Cochrane Headline outcomes only
HR 0.72 [0.63, 0.81]
2 studies · 1473 participants
Low